Oculis Holding AG Logo

Oculis Holding AG

OCS | IC

Overview

Corporate Details

ISIN(s):
CH1242303498 (+1 more)
LEI:
5067005370C2KK324336
Country:
Switzerland
Address:
Bahnhofstrasse 7, 6300 Zug
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Oculis Holding AG is a global, clinical-stage biopharmaceutical company focused on developing innovative treatments to save sight and improve eye care. The company's primary mission is to address significant unmet medical needs in ophthalmology through a patient-centric approach. Its pipeline features several investigational drug candidates, including OCS-01, a topical eye drop using its proprietary OPTIREACH® technology for Diabetic Macular Edema (DME); Licaminlimab (OCS-02) for Dry Eye Disease (DED); and Privosegtor (OCS-05), a neuroprotective agent for Acute Optic Neuritis. Oculis aims to develop highly differentiated, non-invasive, and potentially first-in-class therapies to transform the treatment paradigms for major eye diseases.

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Oculis Holding AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-08-21 22:05
Earnings Release
Oculis birtir uppgjör fyrir annan ársfjórðung 2025 og kynnir áfanga í rekstri f…
Icelandic 20.6 KB
2025-08-21 22:05
Earnings Release
Oculis Reports Q2 2025 Financial Results and Provides Company Update
English 18.3 KB
2025-08-12 10:00
Report Publication Announcement
Oculis to Participate in Upcoming H.C Wainwright 5th Annual Ophthalmology Virtu…
English 4.2 KB
2025-08-01 10:00
Capital/Financing Update
Oculis hækkar lánsheimild sína og fær aðgang að allt að 100 milljónum CHF
Icelandic 8.1 KB
2025-08-01 10:00
Capital/Financing Update
Oculis Upsized Loan Facility to Access up to CHF 100 million
English 7.1 KB
2025-07-09 22:05
Board/Management Information
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
English 948 bytes
2025-06-09 22:05
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
English 940 bytes
2025-06-05 10:00
Post-Annual General Meeting Information
Oculis birtir niðurstöður aðalfundar 2025
Icelandic 7.7 KB
2025-06-05 10:00
Post-Annual General Meeting Information
Oculis Publishes Results of 2025 Annual General Meeting
English 6.4 KB
2025-06-03 23:00
Director's Dealing
Oculis Publishes Notifications of Transactions by Persons Discharging Manageria…
English 949 bytes
2025-06-03 10:00
Regulatory News Service
Oculis to Participate in Upcoming June Investor Conferences
English 4.3 KB
2025-05-09 22:05
Pre-Annual General Meeting Information
Oculis birtir boð á aðalfund
Icelandic 4.6 KB
2025-05-09 22:05
Pre-Annual General Meeting Information
Oculis Publishes Invitation to the Annual General Meeting
English 4.2 KB
2025-05-09 21:05
Pre-Annual General Meeting Information
Oculis Publishes Invitation to the ..
Icelandic 4.6 KB
2025-05-09 21:05
Pre-Annual General Meeting Information
Oculis Publishes Invitation to the ..
English 4.2 KB

Automate Your Workflow. Get a real-time feed of all Oculis Holding AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Oculis Holding AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
1NKEMIA Logo
Offers contract R&D, develops tech platforms, and invests in life sciences ventures.
Spain IKM
2cureX AB Logo
Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.
Sweden 2CUREX
4SC AG Logo
Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.
Sweden ABERA
ABIVAX Logo
Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.
France ABVX
Abliva Logo
A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.
Sweden ABLI
Achiko AG Logo
A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.
Switzerland ACHI
Acticor Biotech Logo
Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.
France ALACT
Active Biotech Logo
Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.
Sweden ACTI
Addex Therapeutics Ltd Logo
Develops oral small molecule drugs, allosteric modulators, for neurological disorders.
Switzerland ADXN